We hypothesized a correlation between TGF-βR2/SMAD4 expression in the tumor, plasma TGF-β1 ligand level, genetic variation in TGF-B pathway and prognosis of pancreatic cancer. This evidence concerns the gene TGFBR2 and familial pancreatic carcinoma.